Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients With Relapsed/Refractory LBCL: Primary Analysis of a Phase Ib/II Study

Elizabeth Budde, MD, PhD, presents data from on mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma.

Related Keywords

Mosunetuzumab Mosun ,International Prognostic Index ,Clin Oncol ,Blood Marrow Transplant ,Ann Arbor ,Mosunetuzumab ,Largeb Cell Lymphoma ,Polatuzumab Vedotin ,Dlbcl ,Relapsed Refractory Lbcl ,Relapsed Refractory Largeb Cell Lymphoma ,Lymphoma ,Overall Response Rate ,